scoping review software covidence Search Results


adaptive covid 19 treatment trial scope  (Gilead Sciences)
99
Gilead Sciences adaptive covid 19 treatment trial scope
( 1 ) Antibodies against the spike protein (raised through vaccination or by adoptive transfer) could block severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from interacting with the angiotensin-converting enzyme 2 (ACE2) receptor on host cells. ( 2 ) Protease inhibitors against the serine protease TMPRSS2 can prevent spike protein cleavage, which is necessary for viral fusion into the host cell. Blocking either ACE2 interaction or viral fusion could prevent the virus from infecting the host cell. ( 3 ) Virus-specific memory CD8 + T cells from a previous vaccination or infection can differentiate into effector cells during rechallenge. When they identify infected cells presenting virus-specific epitopes, they degranulate and kill infected cells before they can produce mature virions. ( 4 ) In a novel treatment method that targets the cytokine storm symptoms, the blood of patients with <t>coronavirus</t> <t>disease</t> <t>2019</t> <t>(COVID-19)</t> can be passed through customized columns that are specially designed to trap pro-inflammatory cytokines, before the purified blood is passed back into patients.
Adaptive Covid 19 Treatment Trial Scope, supplied by Gilead Sciences, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/scoping+review+software+covidence/VEKLURY/pmc07187672-8-5-10
Average 99 stars, based on 1 article reviews
adaptive covid 19 treatment trial scope - by Bioz Stars, 2026-10
99/100 stars
  Buy from Supplier
covidence  (Veritas Health Innovation Ltd)
86
Veritas Health Innovation Ltd covidence
( 1 ) Antibodies against the spike protein (raised through vaccination or by adoptive transfer) could block severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from interacting with the angiotensin-converting enzyme 2 (ACE2) receptor on host cells. ( 2 ) Protease inhibitors against the serine protease TMPRSS2 can prevent spike protein cleavage, which is necessary for viral fusion into the host cell. Blocking either ACE2 interaction or viral fusion could prevent the virus from infecting the host cell. ( 3 ) Virus-specific memory CD8 + T cells from a previous vaccination or infection can differentiate into effector cells during rechallenge. When they identify infected cells presenting virus-specific epitopes, they degranulate and kill infected cells before they can produce mature virions. ( 4 ) In a novel treatment method that targets the cytokine storm symptoms, the blood of patients with <t>coronavirus</t> <t>disease</t> <t>2019</t> <t>(COVID-19)</t> can be passed through customized columns that are specially designed to trap pro-inflammatory cytokines, before the purified blood is passed back into patients.
Covidence, supplied by Veritas Health Innovation Ltd, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/scoping+review+software+covidence/covidence/pmc12872041-53-7-8
Average 86 stars, based on 1 article reviews
covidence - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier

Image Search Results


( 1 ) Antibodies against the spike protein (raised through vaccination or by adoptive transfer) could block severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from interacting with the angiotensin-converting enzyme 2 (ACE2) receptor on host cells. ( 2 ) Protease inhibitors against the serine protease TMPRSS2 can prevent spike protein cleavage, which is necessary for viral fusion into the host cell. Blocking either ACE2 interaction or viral fusion could prevent the virus from infecting the host cell. ( 3 ) Virus-specific memory CD8 + T cells from a previous vaccination or infection can differentiate into effector cells during rechallenge. When they identify infected cells presenting virus-specific epitopes, they degranulate and kill infected cells before they can produce mature virions. ( 4 ) In a novel treatment method that targets the cytokine storm symptoms, the blood of patients with coronavirus disease 2019 (COVID-19) can be passed through customized columns that are specially designed to trap pro-inflammatory cytokines, before the purified blood is passed back into patients.

Journal: Nature Reviews. Immunology

Article Title: The trinity of COVID-19: immunity, inflammation and intervention

doi: 10.1038/s41577-020-0311-8

Figure Lengend Snippet: ( 1 ) Antibodies against the spike protein (raised through vaccination or by adoptive transfer) could block severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from interacting with the angiotensin-converting enzyme 2 (ACE2) receptor on host cells. ( 2 ) Protease inhibitors against the serine protease TMPRSS2 can prevent spike protein cleavage, which is necessary for viral fusion into the host cell. Blocking either ACE2 interaction or viral fusion could prevent the virus from infecting the host cell. ( 3 ) Virus-specific memory CD8 + T cells from a previous vaccination or infection can differentiate into effector cells during rechallenge. When they identify infected cells presenting virus-specific epitopes, they degranulate and kill infected cells before they can produce mature virions. ( 4 ) In a novel treatment method that targets the cytokine storm symptoms, the blood of patients with coronavirus disease 2019 (COVID-19) can be passed through customized columns that are specially designed to trap pro-inflammatory cytokines, before the purified blood is passed back into patients.

Article Snippet: NCT04280705 , USA , Title: Adaptive COVID-19 Treatment Trial Scope: remdesivir treatment of patients with COVID-19.

Techniques: Adoptive Transfer Assay, Blocking Assay, Infection, Purification

Summary of approved interventional clinical trials for COVID-19 as of March 2020

Journal: Nature Reviews. Immunology

Article Title: The trinity of COVID-19: immunity, inflammation and intervention

doi: 10.1038/s41577-020-0311-8

Figure Lengend Snippet: Summary of approved interventional clinical trials for COVID-19 as of March 2020

Article Snippet: NCT04280705 , USA , Title: Adaptive COVID-19 Treatment Trial Scope: remdesivir treatment of patients with COVID-19.

Techniques: Infection, Recombinant, Blocking Assay, Derivative Assay, Western Blot, Injection